Compare Stocks: OLMA, ZLAB, GMTX, and PGEN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GMTX Gemini Therapeutics	$63.61 -2.8%	$75.41	$1.16 ▼ $14.10	$2.76B	-0.12	189,291 shs	771,838 shs
OLMA Olema Pharmaceuticals	$8.23 -0.5%	$10.51	$6.65 ▼ $36.26	$720.13M	2	1.38 million shs	1.07 million shs
PGEN Precigen	$8.54 +4.0%	$7.00	$2.99 ▼ $8.98	$3.04B	0.92	4.70 million shs	6.36 million shs
ZLAB Zai Lab	$24.33 -4.6%	$24.25	$15.96 ▼ $34.07	$2.77B	0.72	860,870 shs	951,837 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GMTX Gemini Therapeutics	-0.62%	-0.95%	-16.77%	-14.16%	-0.94%
OLMA Olema Pharmaceuticals	-4.28%	-8.52%	-21.69%	-34.57%	-25.09%
PGEN Precigen	-4.09%	+6.62%	+19.68%	+45.57%	+145.81%
ZLAB Zai Lab	-3.19%	+0.87%	+0.79%	+33.37%	-25.96%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GMTX Gemini Therapeutics	$63.61 -2.8%	$75.41	$1.16 ▼ $14.10	$2.76B	-0.12	189,291 shs	771,838 shs
OLMA Olema Pharmaceuticals	$8.23 -0.5%	$10.51	$6.65 ▼ $36.26	$720.13M	2	1.38 million shs	1.07 million shs
PGEN Precigen	$8.54 +4.0%	$7.00	$2.99 ▼ $8.98	$3.04B	0.92	4.70 million shs	6.36 million shs
ZLAB Zai Lab	$24.33 -4.6%	$24.25	$15.96 ▼ $34.07	$2.77B	0.72	860,870 shs	951,837 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GMTX Gemini Therapeutics	-0.62%	-0.95%	-16.77%	-14.16%	-0.94%
OLMA Olema Pharmaceuticals	-4.28%	-8.52%	-21.69%	-34.57%	-25.09%
PGEN Precigen	-4.09%	+6.62%	+19.68%	+45.57%	+145.81%
ZLAB Zai Lab	-3.19%	+0.87%	+0.79%	+33.37%	-25.96%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	2.77	Moderate Buy	$40.60	396.03% Upside
PGEN Precigen	2.83	Moderate Buy	$13.67	61.26% Upside
ZLAB Zai Lab	2.71	Moderate Buy	$37.25	52.32% Upside

Current Analyst Ratings Breakdown

Latest OLMA, ZLAB, GMTX, and PGEN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/25/2026	PGEN Precigen	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
9/24/2026	PGEN Precigen	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
9/21/2026	OLMA Olema Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/14/2026	OLMA Olema Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$48.00 ➝ $30.00
8/31/2026	OLMA Olema Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/17/2026	OLMA Olema Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	OLMA Olema Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$52.00 ➝ $46.00
8/11/2026	OLMA Olema Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$38.00 ➝ $36.00
8/11/2026	OLMA Olema Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$59.00
8/7/2026	ZLAB Zai Lab	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$44.00 ➝ $45.00
8/5/2026	PGEN Precigen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$14.00 ➝ $18.00

(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	$5.88 per share	N/A
PGEN Precigen	$9.68M	312.13	N/A	N/A	$0.06 per share	141.25
ZLAB Zai Lab	$449.61M	6.19	N/A	N/A	$6.39 per share	3.83

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
OLMA Olema Pharmaceuticals	-$162.45M	-$2.12	N/A	N/A	N/A	N/A	-48.26%	-43.04%	11/9/2026 (Estimated)
PGEN Precigen	-$250.64M	-$1.04	N/A	11.61	N/A	-183.98%	423.75%	84.39%	11/12/2026 (Estimated)
ZLAB Zai Lab	-$175.54M	-$1.71	N/A	N/A	N/A	-41.86%	-27.43%	-16.72%	11/5/2026 (Estimated)

Latest OLMA, ZLAB, GMTX, and PGEN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	OLMA Olema Pharmaceuticals	-$0.5515	-$0.61	-$0.0585	-$0.61	N/A	N/A
8/6/2026	Q2 2026	ZLAB Zai Lab	-$0.6794	-$0.46	+$0.2194	-$0.50	$103.87 million	$106.31 million
8/4/2026	Q2 2026	PGEN Precigen	-$0.0121	$0.05	+$0.0621	$0.05	$27.98 million	$54.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	N/A	N/A	N/A	N/A	N/A
ZLAB Zai Lab	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GMTX Gemini Therapeutics	N/A	71.49	71.49
OLMA Olema Pharmaceuticals	0.01	8.86	8.86
PGEN Precigen	2.15	4.58	3.89
ZLAB Zai Lab	N/A	2.13	1.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GMTX Gemini Therapeutics	75.42%
OLMA Olema Pharmaceuticals	91.78%
PGEN Precigen	33.51%
ZLAB Zai Lab	41.65%

Insider Ownership

Company	Insider Ownership
GMTX Gemini Therapeutics	12.90%
OLMA Olema Pharmaceuticals	12.56%
PGEN Precigen	41.40%
ZLAB Zai Lab	4.88%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable
OLMA Olema Pharmaceuticals	150	87.50 million	76.51 million	Optionable
PGEN Precigen	47	356.51 million	208.92 million	Optionable
ZLAB Zai Lab	1,784	113.78 million	108.23 million	Optionable

OLMA, ZLAB, GMTX, and PGEN Headlines

Recent News About These Companies

Zai Lab (NASDAQ:ZLAB) Stock Price Down 4.6% - Here's Why

4 hours ago | marketbeat.com

Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

September 29 at 7:27 AM | marketscreener.comM

Zai Lab (NASDAQ:ZLAB) Stock Jumps 3.8% - What's Next?

September 28, 2026 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Stock Bumped Up to "Hold" by Wall Street Zen

September 26, 2026 | americanbankingnews.com

Zai Lab (NASDAQ:ZLAB) Stock Rating Raised to "Hold" at Wall Street Zen

September 26, 2026 | marketbeat.com

Zai Lab Ltd (ZLAB)

September 24, 2026 | in.investing.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Recommendation of "Moderate Buy" from Analysts

September 23, 2026 | americanbankingnews.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Consensus Rating of "Moderate Buy" by Brokerages

September 23, 2026 | marketbeat.com

Zai Lab Limited (ZLAB)

September 11, 2026 | finance.yahoo.com

Seven Fleet Capital Management LP Acquires 58,158 Shares of Zai Lab Limited Unsponsored ADR $ZLAB

September 5, 2026 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Shares Down 4.6% - Here's What Happened

September 4, 2026 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Trading Up 6.9% - Still a Buy?

September 2, 2026 | marketbeat.com

Z.ai shares surge 8% after releasing new AI model running only on Chinese chips

August 26, 2026 | cnbc.com

Zai Lab: Revenue Growth And Zoci's Upside Optionality

August 19, 2026 | seekingalpha.com

Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

August 17, 2026 | businesswire.com

Zai Lab (NASDAQ:ZLAB) CFO Sells 619 Shares

August 14, 2026 | insidertrades.com

Zai Lab (ZLAB) Q2 2026 Earnings Call Transcript

August 13, 2026 | finance.yahoo.com

Is Zai Lab’s (ZLAB) Rising Loss on Softer Revenue Reframing Its Investment-Led Growth Story?

August 10, 2026 | finance.yahoo.com

Zai Lab Limited (ZLAB) Q2 2026 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

Zai Lab Limited 2026 Q2 - Results - Earnings Call Presentation

August 6, 2026 | seekingalpha.com

Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings

August 6, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OLMA, ZLAB, GMTX, and PGEN Company Descriptions

Gemini Therapeutics NASDAQ:GMTX

$63.61 -1.85 (-2.83%)

As of 10/1/2026

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Olema Pharmaceuticals NASDAQ:OLMA

$8.23 -0.04 (-0.48%)

Closing price 04:00 PM Eastern

Extended Trading

$8.23 0.00 (0.00%)

As of 04:10 PM Eastern

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Precigen NASDAQ:PGEN

$8.54 +0.33 (+4.02%)

Closing price 04:00 PM Eastern

Extended Trading

$8.50 -0.04 (-0.44%)

As of 05:01 PM Eastern

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Zai Lab NASDAQ:ZLAB

$24.33 -1.17 (-4.59%)

Closing price 04:00 PM Eastern

Extended Trading

$24.05 -0.28 (-1.14%)

As of 04:43 PM Eastern

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OLMA, ZLAB, GMTX, and PGEN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OLMA, ZLAB, GMTX, and PGEN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OLMA, ZLAB, GMTX, and PGEN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

OLMA, ZLAB, GMTX, and PGEN Company Descriptions

Gemini Therapeutics NASDAQ:GMTX

Olema Pharmaceuticals NASDAQ:OLMA

Precigen NASDAQ:PGEN

Zai Lab NASDAQ:ZLAB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OLMA, ZLAB, GMTX, and PGEN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OLMA, ZLAB, GMTX, and PGEN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OLMA, ZLAB, GMTX, and PGEN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

OLMA, ZLAB, GMTX, and PGEN Company Descriptions

Gemini Therapeutics NASDAQ:GMTX

Olema Pharmaceuticals NASDAQ:OLMA

Precigen NASDAQ:PGEN

Zai Lab NASDAQ:ZLAB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools